SCHEMBL24252369

SCHEMBL24252369

Cc1nnc(N)c2ccc(-c3cc(B(O)O)cc(-c4cccnc4)c3)cc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLG P00747 1/20 0.42
F12 P00748 1/20 0.42
F11 P03951 1/20 0.42
KLKB1 P03952 1/20 0.42
PRSS1 P07477 1/20 0.42
PRSS2 P07478 1/20 0.42
PRSS3 P35030 1/20 0.42
MKNK1 Q9BUB5 6/20 0.40
MKNK2 Q9HBH9 6/20 0.40
DYRK1A Q13627 4/20 0.40
LIMK1 P53667 2/20 0.40
LRRK2 Q5S007 2/20 0.40
CLK4 Q9HAZ1 2/20 0.40
CHEK1 O14757 1/20 0.40
AURKA O14965 1/20 0.40
DAPK3 O43293 1/20 0.40
JAK2 O60674 1/20 0.40
PRKD3 O94806 1/20 0.40
MAP4K4 O95819 1/20 0.40
PAK4 O96013 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Formic Acid SCHEMBL25253326 0.95 ERN1 (0.40) PLGF12F11KLKB1PRSS1
Formic Acid SCHEMBL30453268 0.95 ERN1 (0.40) PLGF12F11KLKB1PRSS1
SCHEMBL26771143 0.92 MKNK1 (0.39) PLGF12F11KLKB1PRSS1
SCHEMBL25253324 0.87 ERN1 (0.39) MKNK1MKNK2DYRK1ALIMK1LRRK2
SCHEMBL30453230 0.83 PLG (0.39) PLGF12F11KLKB1PRSS1
SCHEMBL24252359 0.83 PLG (0.39) PLGF12F11KLKB1PRSS1
SCHEMBL30451657 0.83 PLG (0.56) PLGF12F11KLKB1PRSS1
SCHEMBL24252733 0.83 PLG (0.56) PLGF12F11KLKB1PRSS1
SCHEMBL26771050 0.77 PLG (0.33) PLGF12F11KLKB1PRSS1
SCHEMBL2479963 0.77 CYP2A6 (0.58) MKNK1MKNK2DYRK1ADYRK1BMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 PLG 260/4885F12 29/4885F11 117/4885
US-11814404-B2 Inhibitors of complement factors and uses thereof CFB, CFH, C9 PLG 260/4885F12 29/4885F11 117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.